These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22158433)

  • 1. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.
    Gamboa JL; Pretorius M; Todd-Tzanetos DR; Luther JM; Yu C; Ikizler TA; Brown NJ
    J Am Soc Nephrol; 2012 Feb; 23(2):334-42. PubMed ID: 22158433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?
    Zaritsky JJ; Kalantar-Zadeh K
    J Am Soc Nephrol; 2012 Feb; 23(2):189-91. PubMed ID: 22241894
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
    Gamboa JL; Pretorius M; Sprinkel KC; Brown NJ; Ikizler TA
    BMC Nephrol; 2015 Oct; 16():167. PubMed ID: 26494370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.
    Kaseda R; Tsuchida Y; Gamboa JL; Zhong J; Zhang L; Yang H; Dikalova A; Bian A; Davies S; Fogo AF; Linton MF; Brown NJ; Ikizler TA; Kon V
    Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):582-591. PubMed ID: 29691148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
    Esnault VL; Ekhlas A; Delcroix C; Moutel MG; Nguyen JM
    J Am Soc Nephrol; 2005 Feb; 16(2):474-81. PubMed ID: 15615822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
    Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
    Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
    Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
    Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
    Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
    Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.
    Neri Serneri GG; Boddi M; Modesti PA; Coppo M; Cecioni I; Toscano T; Papa ML; Bandinelli M; Lisi GF; Chiavarelli M
    Circ Res; 2004 Jun; 94(12):1630-7. PubMed ID: 15131005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
    Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
    Slagman MC; Waanders F; Hemmelder MH; Woittiez AJ; Janssen WM; Lambers Heerspink HJ; Navis G; Laverman GD;
    BMJ; 2011 Jul; 343():d4366. PubMed ID: 21791491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
    Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
    Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
    Rezq A; Saad M; El Nozahi M
    Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.